UPDATE 1-Ebola vaccine from GSK fast-tracked into clinical trials
* Trials to vaccinate healthy volunteers from mid-September
* Planned stockpile of up to 10,000 doses for early use
* GSK working with U.S. NIH and international consortium
* U.S. researchers also testing Canadian Ebola vaccine (Updates with further details on clinical trial programme, different vaccines)
By Ben Hirschler and Sharon Begley
LONDON/NEW YORK, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.
The research work is being accelerated with funding from an international consortium, reflecting mounting concern over the worst outbreak of the disease that has killed more than 1,500 people in West Africa.
GSK's candidate vaccine, being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from about mid-September, with the programme then being extended to Gambia and Mali.
Britain's biggest drugmaker said on Thursday the Phase I trials would start as soon as they received ethical and regulatory approvals. Continued...